(AOF) – Onxeo provides an update on the clinical development program for its first-in-class drug candidate AsiDNA: the company reports encouraging preliminary data demonstrated by the interim analysis. This multicenter phase 1b/2 trial aims to evaluate the safety and efficacy of AsiDNA in combination with the PARP inhibitor olaparib in patients with epithelial ovarian cancer, breast cancer and cervical cancer. metastatic castration-resistant prostate (CRPC) who have progressed on previous treatment with PARP inhibitors.
Shefali Agarwal, Chief Executive Officer, says: “This investigational product has been in clinical development in Europe for some years in recurrent solid tumors. In clinical studies performed to date, AsiDNA appears to be well tolerated with encouraging clinical activity in patients The activation of this first study in the United States is an important step towards its global clinical development”.
Onxeo is a clinical-stage biotechnology company specializing in the development of innovative tumor drugs, targeting tumor DNA damage response (DDR) mechanisms and driver oncogenes.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.